Aesica Pharmaceuticals has appointed a team to manage its new European operation following the recent acquisition of three manufacturing sites from UCB in Germany and Italy. The three manufacturing sites are located in Monheim, Zwickau and Pianezza.

Simon Clough has been appointed managing director of the Formulated Products Business Unit, based at the Monheim site. Katy Lineker will serve as finance director of the unit. Also, three long-time Aesica employees have been appointed to support and facilitate the transition following the completion of the acquisition in early 2011: Janette Waterhouse will be based at Zwickau for three months, Ed Wood will spend three months at Pianezza, and Helen Taylor will relocate to Monheim for three months.

Mr. Clough commented, “The acquisition of the three UCB manufacturing sites is strategically crucial for our business as we extend and enhance our current offering and establish a presence in Europe. To have been given the responsibility of directing operations for the Formulate Products Business Unit is an honor and I am committed to ensuring we build upon the strategic partnership we have formed with UCB, as well as introducing new lines of business across the sites. Aesica’s vision is to become the leading supplier of Formulated Products and APIs and I believe that our European operation will play a pivotal role in achieving this.”